OTCMKTS:TRUMY

Terumo (TRUMY) Stock Price, News & Analysis

$16.62
-0.47 (-2.75%)
(As of 04/25/2024 ET)
Today's Range
$16.45
$16.65
50-Day Range
$16.43
$36.78
52-Week Range
$12.56
$20.60
Volume
54,201 shs
Average Volume
54,787 shs
Market Capitalization
$24.78 billion
P/E Ratio
34.99
Dividend Yield
0.66%
Price Target
N/A
TRUMY stock logo

About Terumo Stock (OTCMKTS:TRUMY)

Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stents, intravascular ultrasound systems, imaging catheters, and others; coils, stents, and intrasaccular devices for treating cerebral aneurysm; embolization systems, aspiration catheters, and clot retrievers for treating ischemic stroke and others; oxygenators, cardio-pulmonary bypass systems, and others; and artificial vascular and stent grafts. The Medical Care Solutions Company segment provides syringes, infusion pumps, syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, pain management and nutritious food products, adhesion barriers, and others; blood glucose monitoring systems, disposable needles for pen-injector, insulin patch pumps, blood pressure monitors, digital thermometers, and others; and contract manufacturing of prefilled syringes, devices to pharmaceutical companies for use in drug kits, such as prefillable syringes, needles for pharmaceutical packaging business, and others. The Blood and Cell Technologies Company segment offers blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, cell expansion systems, and others. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was incorporated in 1921 and is headquartered in Tokyo, Japan.

TRUMY Stock Price History

TRUMY Stock News Headlines

The World's First "$20 Trillion Drug?"
One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see gains as high as 113,000%!
Improved Revenue Growth Is Terumo's Next Major Target
The World's First "$20 Trillion Drug?"
One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see gains as high as 113,000%!
Lakewood Company Putting People at Risk?
Ivanka Trump
Trump Reinstated To Facebook And Instagram
OMG. Trump Has Started Texting.
See More Headlines
Receive TRUMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Terumo and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/07/2024
Today
4/26/2024
Fiscal Year End
3/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Medical & hospital equipment
Sub-Industry
N/A
Current Symbol
OTCMKTS:TRUMY
Previous Symbol
NASDAQ:TRUMY
Employees
30,207
Year Founded
1964

Profitability

Net Income
$661.01 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$6.07 billion
Cash Flow
$0.77 per share
Book Value
$5.50 per share

Miscellaneous

Outstanding Shares
1,490,700,000
Free Float
N/A
Market Cap
$24.78 billion
Optionable
Not Optionable
Beta
0.65

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Mr. Shinjiro Sato (Age 64)
    Corporate Advisor & Director
    Comp: $810.32k
  • Mr. Hikaru Samejima (Age 60)
    President, CEO & Director
  • Jin Hagimoto
    CFO, CIO, GM of CFO Office, Controller & Treasury Tax Dept., J-SOX Office, IT Planning Dept. & GBS
  • Shinji Omori
    CTO, GM of DX Promotion Dept. R&D Division and Executive Officer
  • Ms. Miho Mizuguchi
    Executive Officer, Chief Legal Officer and GM of CLO Office, Legal & Compliance Department
  • Tomoko Adachi
    Chief Human Resources Officer & Group Executive Officer
  • Mr. Shoji Hatano (Age 65)
    Director & Corporate Advisor
  • James Rushworth
    Group Executive Officer & Chief Commercial Officer
  • Mr. Kazunori Hirose (Age 60)
    Director & Group Managing Executive Officer
  • Itaru Sakaguchi
    Group Managing Executive Officer

TRUMY Stock Analysis - Frequently Asked Questions

Should I buy or sell Terumo stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Terumo in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" TRUMY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TRUMY, but not buy additional shares or sell existing shares.
View TRUMY analyst ratings
or view top-rated stocks.

How have TRUMY shares performed in 2024?

Terumo's stock was trading at $16.31 at the beginning of 2024. Since then, TRUMY shares have increased by 1.9% and is now trading at $16.62.
View the best growth stocks for 2024 here
.

Are investors shorting Terumo?

Terumo saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 3,800 shares, an increase of 46.2% from the March 31st total of 2,600 shares. Based on an average trading volume of 137,800 shares, the short-interest ratio is presently 0.0 days.
View Terumo's Short Interest
.

How were Terumo's earnings last quarter?

Terumo Co. (OTCMKTS:TRUMY) released its earnings results on Wednesday, February, 7th. The company reported $0.14 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.14. The company had revenue of $1.62 billion for the quarter. Terumo had a net margin of 11.14% and a trailing twelve-month return on equity of 8.26%.

Is Terumo a good dividend stock?

Terumo (OTCMKTS:TRUMY) pays an annual dividend of $0.11 per share and currently has a dividend yield of 0.63%. The dividend payout ratio is 23.16%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, TRUMY will have a dividend payout ratio of 16.42% next year. This indicates that the company will be able to sustain or increase its dividend.

When did Terumo's stock split?

Terumo's stock split before market open on Thursday, March 28th 2024. The 2-1 split was announced on Thursday, March 28th 2024. The newly minted shares were distributed to shareholders after the closing bell on Thursday, March 28th 2024. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

How do I buy shares of Terumo?

Shares of TRUMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:TRUMY) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners